← Leaderboards
Jia Yu
Icahn School Of Medicine At Mount Sinai
$88,718
Attributed
$88,718
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $41.2K · FY2016–18$50K$37.5K$25K$12.5K$0
'16
'17
'18
Funding mix
By agency
NIH$88,718 · 1
By mechanism
F31$88,718 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Sarah E Millar$29,975,437
- Amaia Lujambio$5,368,450
- Dolores Hambardzumyan$10,720,002
- Ernesto Guccione$11,143,318
- Bachir Taouli$9,208,757
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsAnalogAnimal ModelAnimalsBaseBay 54-9085BiochemicalBiochemical GeneticsCancer PatientCell Cycle RegulationCell LineCellsCell SurvivalChemical GeneticsChromatin RemodelingClinical TrialsCoculture TechniquesCodeCollaborationsCostCytotoxicDiagnosisDrosophila GenusDrug Effect Disorder
Grant awards (3)
Improving Sorafenib; a multi-targeted kinase inhibitor used for the treatment of hepatocellular carcinoma by mechanistically dissecting out its underlying targets and anti-targets$6,698
F31 · FY2018 · CA · contact PI
Improving Sorafenib; a multi-targeted kinase inhibitor used for the treatment of hepatocellular carcinoma by mechanistically dissecting out its underlying targets and anti-targets$41,244
F31 · FY2017 · CA · contact PI
Improving Sorafenib; a multi-targeted kinase inhibitor used for the treatment of hepatocellular carcinoma by mechanistically dissecting out its underlying targets and anti-targets$40,776
F31 · FY2016 · CA · contact PI